RANCHO CUCAMONGA, CA / ACCESS Newswire / July 14, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH), a bio-pharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, has announced a multi-year expansion of its U.S. manufacturing operations at its headquarters in Rancho Cucamonga, California. The company plans to quadruple its production capacity at this location over the next three to five years, reinforcing its commitment to domestic pharmaceutical manufacturing and strengthening supply chain resilience.

This strategic initiative represents the most substantial investment in domestic infrastructure in the company's history. It will feature a new state-of-the-art production plant, expanded automation, and the integration of advanced technologies to support the development and manufacture of critical medications, including supporting the production of new pipeline candidates. Once completed, the company expects to create new jobs in research and development, engineering, manufacturing, and quality operations.

"Expanding our domestic manufacturing footprint is not only a strategic milestone for Amphastar but a reaffirmation of our commitment to producing essential medicines right here in the United States," said Dr. Jack Zhang, Amphastar's President and CEO. "All of our finished pharmaceutical products are proudly manufactured in the U.S., and this long-term investment strengthens the commitment, enhancing our ability to deliver greater flexibility, agility, and quality to the healthcare providers and patients who depend on our products every day."

Amphastar will continue working in close partnership with all levels of government leadership to ensure sustainable growth, workforce development, and alignment with economic and public health priorities.

Company Information

Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.

Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar^®, BAQSIMI^®, Primatene MIST^®, REXTOVY^TM, Amphadase^®, and Cortrosyn^®, are the property of Amphastar.

Forward Looking Statements

All statements in this press release referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding expansion of our headquarters, including quadrupling our production capacity and manufacturing capabilities, the resilience of our supply chain, our ability to expand our automation capabilities and integrate advanced technologies, our ability to create new jobs in the future, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ending March 31, 2025, filed with the SEC on May 8, 2025, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI^®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

Contact Information:

Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416

SOURCE: Amphastar Pharmaceuticals, Inc.